BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
EGFR
,
Angiogenesis
,
Pseudomonas infection
,
Neuron
,
Laser capture microdissection
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
ponatinib
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
LCN2
CRIP1
MAL
RBP4
DHRS2
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
response to stress
regulation of nitrogen compound metabolic process
regulation of cellular component organization
organic cyclic compound binding
heterocyclic compound binding
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Lung adenocarcinoma LC-2/ad parental and ponatinib-resistant PR1 and PR2 cells
Left ventricle of high fat diet-fed ApoE KO mice treated with tyrosine kinase inhibitor ponatinib
Multiple cancer cell lines treated with 32 kinase inhibitors
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
Explore Curated Studies Results
Literature
Most Relevant Literature
Evaluation of Cardiac Adverse Events with Ponatinib Using a Spontaneous Reporting Database.
Potential risk of drug-drug interactions of ponatinib via inhibition against human UDP-glucuronosylt…
Ponatinib-induced eruptive nevi and melanocytic proliferation.
Incidence of adverse effects in patients receiving ponatinib with concomitant azole antifungals.
Response-Based Dosing for Ponatinib: Model-Based Analyses of the Dose-Ranging OPTIC Study.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Compassionate Use Ponatinib
Vascular Cardiotoxicity of Ponatinib
Expanded Access Program of Ponatinib
Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma
Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ